

By: Oliverson

H.B. No. 3922

Substitute the following for H.B. No. 3922:

By: Oliverson

C.S.H.B. No. 3922

A BILL TO BE ENTITLED

1 AN ACT

2 relating to information provided by health care providers and
3 hospitals to certain patients regarding pharmaceutical
4 manufacturer patient assistance programs for insulin.

5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

6 SECTION 1. Subchapter N, Chapter 531, Government Code, is
7 amended by adding Section 531.509 to read as follows:

8 Sec. 531.509. INFORMATION ON PHARMACEUTICAL MANUFACTURER
9 PATIENT ASSISTANCE PROGRAMS FOR INSULIN. (a) This section applies
10 to health care providers and hospitals that receive uncompensated
11 care pool payments from the commission, including:

12 (1) federally qualified health centers as defined by
13 42 U.S.C. Section 1396d(1)(2)(B);

14 (2) rural health clinics as defined by 42 U.S.C.
15 Section 1396d(1)(1); and

16 (3) physician group practices.

17 (b) A health care provider or hospital to which this section
18 applies shall provide to patients who have diabetes and require
19 insulin information regarding the availability of pharmaceutical
20 manufacturer patient assistance programs, including copay cards,
21 that may reduce the cost of insulin to the patients.

22 (c) The executive commissioner shall adopt rules to
23 implement this section.

24 SECTION 2. If before implementing any provision of this Act

1 a state agency determines that a waiver or authorization from a
2 federal agency is necessary for implementation of that provision,
3 the agency affected by the provision shall request the waiver or
4 authorization and may delay implementing that provision until the
5 waiver or authorization is granted.

6 SECTION 3. This Act takes effect September 1, 2021.